Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915944 | 0.93 | POLB (0.37) | BRD4SERPINE1KMT2APOLBMEN1 | |
| SCHEMBL917748 | 0.93 | KMT2A (0.36) | BRD4SERPINE1KMT2APOLBMEN1 | |
| SCHEMBL916311 | 0.92 | BRD4 (0.35) | BRD4SERPINE1KMT2APOLBMEN1 | |
| SCHEMBL916638 | 0.89 | BRD4 (0.39) | BRD4SERPINE1KMT2APOLBMEN1 | |
| SCHEMBL916730 | 0.89 | BRD4 (0.39) | BRD4SERPINE1KMT2APOLBMEN1 | |
| SCHEMBL916614 | 0.88 | GAA (0.36) | BRD4KMT2APOLBMEN1MAPK1 | |
| SCHEMBL917442 | 0.86 | BRD4 (0.35) | BRD4KMT2APOLBMEN1MAPK1 | |
| SCHEMBL917282 | 0.84 | BRD4 (0.36) | BRD4KMT2APOLBMEN1MAPK1 | |
| SCHEMBL916201 | 0.81 | KDM4E (0.36) | SERPINE1KMT2APOLBMEN1MAPK1 | |
| SCHEMBL709821 | 0.80 | CHRM1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1742912-A1 | NOVEL ANDROGENS | N.V. Organon (NL) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | BRD4 867/4885SERPINE1 820/4885KMT2A 1595/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | BRD4 688/4885SERPINE1 3338/4885KMT2A 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.